Amitiza

Merek dagang preparat lubiprostone.

Amitiza (Wikipedia)
Lubiprostone
Lubiprostone.svg
Clinical data
Trade names Amitiza
AHFS/Drugs.com Monograph
MedlinePlus a607034
License data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability Negligible
Protein binding 94%
Metabolism Extensive, CYP not involved
Biological half-life Unknown (lubiprostone)
0.9–1.4 hours (main metabolite)
Excretion Renal (60%) and fecal (30%)
Identifiers
Synonyms Amitiza
RU-0211
SPI-0211
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C20H32F2O5
Molar mass 390.462 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Lubiprostone (rINN, marketed under the trade name Amitiza among others) is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation.

It was initially approved by the U.S. Food and Drug Administration (FDA) in 2006 and recommended for use in the by the National Institute for Health and Care Excellence (NICE) in 2014. It is expensive as of 2017, with the cost to the NHS being £29.68 per 24mg 28-cap pack as of April 2017.